TOVX vs TPST

Theriva Biologics, Inc. vs Tempest Therapeutics, Inc. — Valuation Comparison 2026

TOVX

Pharmaceutical Preparations
Theriva Biologics, Inc.
Quality
4.0
out of 10
Value Trap
37
LOW
Price
$0.28
Last close
Models
8/13
Active
VS

TPST

Pharmaceutical Preparations
Tempest Therapeutics, Inc.
Quality
3.2
out of 10
Value Trap
36
LOW
Price
$1.53
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TOVX Fair ValueTOVX Upside TPST Fair ValueTPST Upside
Bayesian DCF Intrinsic $0.23 -18.8% $0.34 -78.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.05 -87.6% $0.11 -94.8%
Dynamic NAV Asset-Based $0.20 -28.6% $5.58 +264.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TOVX vs TPST — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TOVX vs TPST — Which Stock Is More Undervalued?

TOVX scores higher with a 4.0/10 quality rating vs TPST's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Theriva Biologics, Inc. (TOVX) and Tempest Therapeutics, Inc. (TPST) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TOVX currently trades at $0.28 with a QOC of 4.0/10, while TPST trades at $1.53 with a QOC of 3.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).